Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nimotuzumab (Center for Molecular Immunology)
- Development stage
- Unknown
- Lead developer
- Henlius
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
**Nimotuzumab** is a humanized IgG1 monoclonal antibody targeting the extracellular domain of epidermal growth factor receptor. It inhibits EGFR ligand binding and receptor activation, thereby suppressing EGFR-driven tumor-cell proliferation and survival signaling; Fc-mediated antitumor immune activity may also contribute. The term \"Nituzumab\" in the Fujian Medical University Cancer Hospital cervical-cancer trial is a spelling variant of nimotuzumab. In NCT06455072, nimotuzumab is being evaluated intravenously with serplulimab and stereotactic body radiotherapy for recurrent advanced cervical squamous cell carcinoma after prior treatment.
- Brand names
- BIOMAb EGFRCIMAherTaixinshengTheraCIMTheraloc
- Other names
- h-R3h-R-3h-R 3HR3HR-3HR 3NituzumabOSAG 101OSAG101OSAG-101Thera-CIM-hR3Thera-CIM-hR-3Thera-CIM-hR 3TheraCIM-hR3TheraCIM-hR-3TheraCIM-hR 3
02
Targets
EGFR T790M (Epidermal growth factor receptor T790M mutant)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on nimotuzumab (Center for Molecular Immunology).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nimotuzumab (Center for Molecular Immunology).